No products in the cart.
GEN-CANCER
25,000 EGP
Identify those at risk may help with early intervention
Cancer is a common disease with a lifetime risk of affecting about 1 in 4 individuals in the world. Majority of these cancers are sporadic. Approximately 5-10% of all cancer cases are thought to involve hereditary predisposition. Identifying those at risk may help with early intervention through additional screening, increased surveillance & other interventions.
GEN-CANCER panels employ targeted NGS to analyze a set of genes associated with hereditary cancer syndromes, identifying pathogenic variants that confer an increased risk of developing certain cancers.
You will receive your report via Our Reports GEN-Portal within 45 business days.
-
- Detect Early, prevent!
- Shrink the monster with 99% survival rate for early detected cases
- Simple Saliva or Blood test
- Approved by American College of Medical Genetics
Complimentary 30-minute genetic consultation included
Description
- High depth of coverage (>500x) ensures accurate detection of single nucleotide variants, small insertions/deletions, and copy number variations
- Bioinformatics analysis pipeline prioritizes variants based on population frequency, predicted pathogenicity, and clinical relevance
- Provides valuable information for personalized cancer risk assessment, surveillance, and prevention strategies
- Suitable for individuals with a personal or family history of cancer, or those meeting national guidelines for genetic testing (e.g., NCCN)
Turn Around Time (TAT): 45 working days
Sample type: Simple Swab
Availability: Online (Home kit) or branch Visit
Report: Online GEN-Portal
You may also like…
-
GEN-ORIGINS
10,000 EGP -
GEN-OBREAST
20,000 EGP -